Breast Cancer Research and Treatment

, Volume 31, Issue 1, pp 73–82

The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

  • T. J. Powles
  • A. L. Jones
  • S. E. Ashley
  • M. E. R. O'Brien
  • V. A. Tidy
  • J. Treleavan
  • D. Cosgrove
  • A. G. Nash
  • N. Sacks
  • M. Baum
  • J. A. McKinna
  • J. B. Davey
Article

DOI: 10.1007/BF00689678

Cite this article as:
Powles, T.J., Jones, A.L., Ashley, S.E. et al. Breast Cancer Res Tr (1994) 31: 73. doi:10.1007/BF00689678

Abstract

A pilot randomised placebo controlled trial using tamoxifen in healthy women at increased risk of developing breast cancer, has been undertaken in order to evaluate the problems of accrual, acute symptomatic toxicity, compliance, and safety as a basis for subsequent large national multicentre trials designed to test whether tamoxifen can chemoprevent breast cancer.

From October 1986 until June 1993, 2012 healthy women with an increased risk of developing breast cancer, usually because of a strong family history, were randomly allocated to receive tamoxifen 20 mgs/day or placebo for up to 8 years if possible.

Accrual remained high in spite of extensive informed consent regarding potential risk. Acute symptomatic toxicity was low for participants on tamoxifen or placebo and compliance remained correspondingly high with a predicted 77% of women on tamoxifen and 82% of women on placebo continuing medication at 5 years. There was a significant increase in hot flushes (34% versus 20%) mostly in premenopausal women (p < 0.005), vaginal discharge (16% versus 4%, p < 0.005), and menstrual irregularities (14% versus 9%, p < 0.005). The requirements for hormone replacement therapy for women on tamoxifen or placebo were the same.

Safety monitoring indicates no adverse anti oestrogenic effects of tamoxifen. There was no obvious effect of tamoxifen on bone mineral densities (single photon radial absorption). The fibrinogen and antithrombin III were both lowered, resulting in no observed detrimental effect on the ratio of these clotting factors. There was a significant reduction in the serum cholesterol maintained out to 5 years. Annual pelvic assessment using transvaginal ultrasound indicates an increased incidence of uterine fibromata and benign ovarian cysts. These results have encouraged the commencement of the NSABP national trial in the USA, and the subsequent start of national trials in Italy and the UK, which together should provide sufficient evidence to evaluate the efficacy of tamoxifen for prevention of breast cancer.

Key words

chemoprevention compliance tamoxifen toxicity 

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • T. J. Powles
    • 1
  • A. L. Jones
    • 1
  • S. E. Ashley
    • 1
  • M. E. R. O'Brien
    • 1
  • V. A. Tidy
    • 1
  • J. Treleavan
    • 1
  • D. Cosgrove
    • 1
  • A. G. Nash
    • 1
  • N. Sacks
    • 1
  • M. Baum
    • 1
  • J. A. McKinna
    • 1
  • J. B. Davey
    • 1
  1. 1.Breast UnitRoyal Marsden Hospital, London and SurreySutton, SurreyUK

Personalised recommendations